Sutro Biopharma (STRO) Times Interest Earned (2017 - 2026)
Sutro Biopharma (STRO) posted Times Interest Earned of $5.36 for Q4 2025, up 317.94% sequentially from -$2.46 in Q3 2025, and up 102.03% YoY from $2.65 in Q4 2024.
Sutro Biopharma (STRO) Times Interest Earned (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Times Interest Earned for 9 years, with the latest figure at $5.36 in Q4 2025.
- Quarterly Times Interest Earned rose 102.03% year-over-year to $5.36 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $70.29 (down 49.09% YoY) and the FY2025 annual result came in at -$0.58, up 44.41% from the prior year.
- Times Interest Earned climbed to $5.36 in Q4 2025 per STRO's latest filing, from -$2.46 in the prior quarter.
- Over five years, Times Interest Earned peaked at $5.36 in Q4 2025 and troughed at -$264.2 in Q4 2024.
- A 5-year average of -$37.8 and a median of -$9.48 in 2021 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2025: Times Interest Earned sank 11254.32% in 2022, then jumped 102.03% in 2025.
- Over 5 years, Times Interest Earned stood at -$9.53 in 2021, then sank by 1109.13% to -$115.27 in 2022, then jumped by 91.82% to -$9.43 in 2023, then plunged by 2700.48% to -$264.2 in 2024, then surged by 102.03% to $5.36 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered $5.36, -$2.46, and -$0.15 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | -2.56 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.56 |
| Dec 31, 2025 | 5.36 |
| Sep 30, 2025 | -2.46 |
| Jun 30, 2025 | -0.15 |
| Mar 31, 2025 | -29.79 |
| Dec 31, 2024 | -264.20 |
| Sep 30, 2024 | -8.19 |
| Jun 30, 2024 | -5.87 |
| Mar 31, 2024 | -24.60 |
| Dec 31, 2023 | -9.43 |
| Sep 30, 2023 | -146.71 |
| Jun 30, 2023 | -1.14 |
| Mar 31, 2023 | -24.85 |
| Dec 31, 2022 | -115.27 |
| Sep 30, 2022 | -7.61 |
| Jun 30, 2022 | -32.30 |
| Mar 31, 2022 | -55.90 |
| Dec 31, 2021 | -9.53 |
| Sep 30, 2021 | -0.97 |
| Jun 30, 2021 | -0.28 |